The aberrantly expressed signal transducer and activator of transcription 3 (STAT3) predicts poor prognosis, primarily in estrogen receptor positive (ER(+)) breast cancers. Activated STAT3 is overexpressed in luminal A subtype cells. The mechanisms contributing to the prognosis and/or subtype relevant features of STAT3 in ER(+) breast cancers are through multiple interacting regulatory pathways, including STAT3-MYC, STAT3-ERα, and STAT3-MYC-ERα interactions, as well as the direct action of activated STAT3. These data predict malignant events, treatment responses and a novel enhancer of tamoxifen resistance. The inferred crosstalk between ERα and STAT3 in regulating their shared target gene-METAP2 is partially validated in the luminal B breast cancer cell line-MCF7. Taken together, we identify a poor prognosis relevant gene set within the STAT3 network and a robust one in a subset of patients. VEGFA, ABL1, LYN, IGF2R and STAT3 are suggested therapeutic targets for further study based upon the degree of differential expression in our model.
Introduction
Breast cancer (BC) is a global health problem and, in Taiwan, BC has replaced cervical cancer as the most common female cancer. 1 The inherent genetic complexity and heterogeneity of breast cancer limits the prognostication value of many current model systems, as well as the ability to predict specific cancer identities from generalized information. An increasing number of transcription factor regulatory networks play unique roles in mammary epithelial development and tumorigenesis.
2 STAT3 is a transcriptional regulator that is involved in mammary gland development, and elevated STAT3 has been widely observed in breast cancers. [3] [4] [5] [6] [7] Alterations in STAT3 transcription programs may be a major switch in determining roles and clinical outcomes among breast cancer subtypes. To date, the prognostic value of STAT3 in human breast cancer remains unclear. 8 Dissection of the global transcriptome in a clinical breast cancer cohort study suggests a role for STAT3 in coupling with MYC. And this, in turn, conditions a broad spectrum of pathophysiological effects in early development of estrogen receptor α negative (ER(−)) breast cancers, typically in triple negatives (TN). 9 In silico studies demonstrate that some STAT3 target genes are potentially unfavorable prognostic markers in 77 breast cancer patients with ER(−) IDCs. However, the prognostic features of STAT3 in an ER(−) breast cancer setting have not been identified. In order to assess the predictive value of STAT3 pathway components, we evaluated clinical responses relative to STAT3 activities in 2 breast cancer patient populations with 77 ER(−) IDCs 9 and 90 ER(+) IDCs, respectively. STATs are known downstream targets of nongenomic ER actions in breast cancer cell models. 10 Miller et al 11 summarized routes for reciprocal crosstalk between estrogen receptor (ERα) and growth factor receptor signaling pathways. They indicated that membrane ER might activate oncogenic kinases to promote endocrine resistance; however, these mechanisms remain to be proven clinically. Importantly, the status of STAT3 as a target to treat ER(+) breast cancer with TAM resistance remains unclear. Using a network approach, it is possible to evaluate interactions between 2 transcription factors (ERα, STAT3) in regulating genes that may be causally associated with de novo or acquired resistance to endocrine therapy. Using this approach, we evaluated the role of STAT3 as a survival predictor gene based upon altered STAT3 transcriptional regulatory activity in an ER(+) breast cancer model system, consisting of 4 subtypes (groups IE, IIE, luminal A and B).
STAT3 can be activated by classical and nonclassical mechanisms. 12, 13 The cooperation of both tyrosine (Tyr705) and serine (Ser727) phosphorylation is necessary for full classical activation of STAT3. For instance, STAT3 can be activated by the 17-β-estradiol-induced pathway via phosphorylation at Tyr705 and Ser727. 12 Unphosphorylated STAT3 transcription factor can also bind DNA according to the non-classical model. 13 Greten FR et al 14 reported that a STAT3-dependent transcriptional program, in part, is triggered by an excess concentration of activating cytokines secreted in an autocrine or paracrine manner by tumor and stromal cells. Cytokine activation of STAT3 is constitutively activated by JAKs and JAK/STAT3 promotes breast cancer progression.
15 STAT3 is also down-regulated by the chemodrugs 5-fluorouracil and gemcitabine in a MCF-7 cell model 16 and by dehydrocostuslactone (DHE) in MCF-7 and MDA-MB231 cell models. 17 At least 3 signal transduction pathways including MAPK, PI3-kinase, and Src-kinase pathways are required for 17-β-estradiol induced activation of a STAT-regulated promoter. 10 , 18 Hart et al 19 further showed that STAT3 activation is essential for transformation in PI3K-transformed cells. Inhibition of PI3K prevents STAT3 phosphorylation.
Herein, we find that high STAT3 mRNA levels in tumor tissue is a marker for poor prognosis and dissect the STAT3 network interactions as a basis for developing a predictive model. Finally, we identify major components of the STAT3 transcriptional regulatory network in silico that may be prognostic markers and therapeutic targets in ER(+) breast cancers in a subtype relevant manner.
Materials and Methods

Features of surgical specimens for generating the dataset
Microarray data analyses
A genome-wide gene expression profile per breast tumor specimen was analyzed using an Agilent Human 1 A (version 2) oligonucleotide microarray (half a genome size: 22 k) (Agilent technologies, USA). Quality control data (QC data) was established for 3 breast cancer biomarker genes-ESR1 (N = 151), PGR (N = 151) and ERBB2 (N = 151) using the same total ribonucleic acid (RNA) samples used for generating the gene expression profiles in 181 infiltrating ductal carcinomas (N = 181). The missing data for 30 samples (N = 30) was due to insufficient RNA for quantitative polymerase chain analysis (qPCR).
The qPCR procedure was done according to Kuo et al. 20 4 primer IDs (Applied Biosystems, Foster City, CA, USA) designated as HT-A003, HT-A004, HT-A006 and a control primer ID as HH-T001 (TIB MOL BIOL, Germany) were used for amplification of the complementary deoxyribonucleic acid (cDNA) for PR, HER-2/neu, ER and the TATA box binding protein (TBP), respectively. Quality control data are shown in Figure 8 .
The heatmaps were displayed after unsupervised hierarchical clustering using R package (version 2.15.1). The "hcluster" function in the "stats" package was utilized to perform the unsupervised clustering. The heatmap was produced by the "rect" function to generate a customized view of the subcohorts. Gene Spring GX7.3.1 was used for generating Venn diagrams. ANOVA tests and the statistical methods for establishing the STAT3 transcriptional regulatory network were performed. 9 Kaplan-Meier survival analyses 21 were done using the "survival" package in R (version 2.15.1) for the gene profiles of 90 A cohort, 91 A cohort, 181 A cohort or the extracted gene pools of interest in the assigned cohorts. To quantify the weight of hazard ratios associated with the prognostic gene signature and the traditional prognostic factors in a given cohort of interest, both univariate and multivariate COX proportional hazard (COXPH) regression model in R package were performed.
experimental design
Previously, we demonstrated that a new method, combining the coefficient of intrinsic dependence (CID) and Galton-Pierson's Correlation Coefficient (GPCC), potentially has significant advantages in predicting network responses at the transcriptome level when using a systems biology approach. 22 We found that the nuclear receptor ERα, which is a ligand dependent transcription factor, is activated by the environmental trigger (i.e. estrogen) in the breast cancer specimens. As a result, the relationship between the environmental trigger and a phenotype (i.e. the ERα transcriptional regulatory network) could be functionally dissected from the gene expression profiles in the breast tumor population. To specifically classify regulatory mechanisms impacting ERα functional transcription activities, we established the multivariate space of the ERα transcriptional regulatory network using multivariate CID. 23 Although this network analysis has proven to be statistically significant relative to specificity and sensitivity, the sensitivity of interactions among gene products 22 was not established. This was due to the complexity and size of TFs that are potentially functioning in the gene expression profile consisting of half a genome size, given that the predicted number of human putative transcription factors genome-wide is between 1,850 and 4,105. 24 Moreover, each transcription factor has its unique regulatory mechanism and most have not been studied in breast cancers. Therefore, we designed a series supervised approach to reduce the confounder effects due to sampling, cohort composition and gene expression data after processing.
This network analysis is based on the prior data related to the functional status of a given TF in a given sample population. The method has been modified to increase the specificity and sensitivity of network analysis. Firstly, we have modified the procedure for CID via replacing the quantile clustering by hierarchical clustering before subgrouping the data for CID analysis. Hierarchical clustering mimics the biological event in which a functional TF with relatively similar gene expression levels may regulate its target genes in a similar manner under similar environments. Secondly, we have designed a dataset consisting of 2 subcohorts with different features of interest for network analysis. Thirdly, we established the predicted networks of a TF, which has transcript variants acting as the same target gene regulator, as a function of the whole network of the TF. Finally, we optimized the subgrouping strategy to be 1/10th for CID analysis. This effectively localizes the most relevant transcriptional regulatory mechanism of interest to a small subgroup of tumor specimens (i.e. the highest subCID value) as compared to that in other subgroups.
Herein, we designed specific subcohort combinations for univariate CIDUGPCC analysis based on data from ANOVA tests, hypothesis testing and consideration of the reduction of the confounder effects. For instance, we predict a clinically significant transcriptional regulatory network for a TF x by combining subcohorts, which have opposite status of a given clinical parameter, to run CIDUGPCC analysis on the TF x .
CIDUGPCC analysis is an established statistical measure for building a network based on significance in non-linear or in linear associations. Biologically, such combined measurements allow the gene expression relationship between a transcription factor and its predicted target gene to be identified in a given population. When a gene pool is identified as the potential target of a transcription factor, the relationship among them can be linked to form a transcriptional regulatory network. 9, 22 We investigated networks of MYC, STAT3, ESR1, ARNT and FOXC1 in this study.
The mRNA expression levels of ESR1 are not linearly correlated with ERα protein levels within ER(+) IDCs. 23 Additionally, STAT3 mRNA levels are elevated preferentially in the HER(−) IDCs group. To predict subtype-enriched transcriptional regulatory programs of ERα and STAT3, we analyzed group IE (61 A), group IIE (29 A), luminal A (42 A) and luminal B (30 A). The counter cohort (29 A) to these subcohorts was ERBB2+ (i.e. ER(−)PR(−) HER(+)). Dataset (119 A), comprised of ERBB2+ (29 A), groups IE (61 A) and IIE (29 A) and dataset (101 A) comprised of ERBB2+ (29 A), luminal A (42 A) and luminal B (30 A) were used for univariate and bivariate network studies. 22, 23 To evaluate crosstalk between ERα and STAT3 at the transcriptional level, we used the bivariate CID method to extract shared regulatory network.
Venn diagram analysis was performed to identify overlapping and/or non-overlapping gene pools related to the feature of interest. The combinatorial interactions between transcription factors were further investigated to dissect the regulatory mechanisms on their shared target genes (see examples in Suppl. 2 of Additional file 1). Gene annotation was done according to the Gene References Into Function (Gene RIFs of NCBI) and Gene Spring GX7.3.1. Western blot analysis MCF-7 cells were treated with appropriate amounts of estrogen, anti-estrogen or both for 48 hours before cells were harvested for total protein extraction. Western blot analysis was performed as described 25 with a few modifications.
In vitro
To each well dish in 6-well plates, 0.2 ml of the ice-cold lysis buffer (20 mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1% TritonX100, 1 mM β-glycerophosphate, 1 mg/ml leupeptin and aprotinin and 1 mM phenylmethylsulphonyl fluoride) was added. The lysed cells were prepared by pulse-sonication and centrifugation at 14,000 rpm for 10 minutes. Cell lysate samples (60 µg total protein/ lane) were loaded in a 7.5% polyacrylamide gel containing 1% SDS (SDS-PAGE) for gel electrophoresis. Fractionated proteins were transferred to a nitrocellulose membrane and probed with primary antibodies in 5% bovine serum albumin dissolved in Tris-buffered saline with 0.05% Tween 20 and 10% non-fat milk. Secondary antibodies conjugated to horseradish peroxidase were then applied. Chemiluminescent substrate of horseradish peroxidase was added at the final step. The specific protein bands labeled with a final chemiluminescent dye were visualized by exposing the membrane to X-ray film. Western blot analysis to detect p67 was done using polyclonal rat p67 antibody. 26 β-actin in each lane was probed with antiβ-actin antibody (Sigma Diagnostics, St. Louis, MO, USA) as the loading control.
In vivo validation and supporting documents
Angiosonograms were gathered at NTUH. Sonograms of the cohort study and literature documentations were used to partially validate the network prediction.
Results and Discussion
Network analysis was utilized to biochemical profiling of 12 signal transduction pathway activities, the clinical relevance of ten clinical parameters, prognosis relevant events, and other malignant phenotypes including proliferation, the Warburg effect, sustained angiogenesis, and ES like epithelial mesenchymal transition. STAT3 is projected to differentially regulate these pathophysiological activities and some additional transcription factors are suggested as co-regulators of STAT3 to regulate these cellular activities. However, further time course studies in model systems are required to validate transcriptional roles of STAT3 in regulating tumorigenesis because clinical tumor samples used in our studies were collected at a single time point. overlapping network of MYC and STAT3 (6,579 probes in Fig. 2B and Table S1 .7 in Suppl. 1 of Additional file 1), which was determined to be significantly relevant in both ER(+) IDCs and in mitotic count. Relevant to ER positive breast cancers, the clinically significant MYC and STAT3 overlapping network (identified based upon approximately 122 TFs and/or their subunits in this network as shown in Table  S1 .7 in Suppl. 1 of Additional file 1) shows increased regulation of genes associated with tumor size (size), mitotic count (MC), lymphovascular invasion (LVI) than regulation of those associated with histological grade (grade) and lymph node metastasis status (LYM). These results indicate relatively less regulation of genes associated with nuclear pleomorphism (NP), cancer stage (stage), tubule formation (TF), number of lymph node metastasis (LNM) and age ( Fig. 2C and Suppl. 3). Many TFs (about 144 TFs and/or their subunits in Table S1 .3; about 122 TFs and/or their subunits in Table S1 .7) are partners of STAT3 and possibly participate in co-regulating those gene pools. We summarize the clinically significant gene pools in Figure 2C that may be relevant to ER(+) tumor development due to MYC and STAT3 regulation of their shared target genes.
STAT3 has a large number of transcription factors other than MYC as potential regulatory partners (Fig. 2B , Table S1 .7 in Suppl. 1 of Additional file 1) and these may control tumor fate in multiple patho physiological events ( Fig. 2C ) and in deregulated biochemical events (Fig. 2D) . Notably, Figure 2C indicates a broad spectrum of early clinically relevant and luminal A subtype enriched pathological features affected by transcriptional regulation of STAT3. Unexpectedly, among 10 clinical parameters we found that tumor size shares the largest gene pool with the overlapping network of STAT3 and MYC (Fig. 2C) . This suggests that a pre-programmed transcriptional event of STAT3 in coupling with MYC may slightly shift the preferential influence of STAT3 for a series of pathophysiological features. 0  30  8  15  15  1  31  21  27  15  NA  0  0  0  0  grade  1  19  4  11  3  2  31  12  23  15  3  8  9  6  10  NA  3  4  2  2  TF  1  2  0  2  0  2  21  8  9  12  3  32  16  26  16  NA  6  5  5  2  NP  1  6  0  3  0  2  33  13  21  15  3  16  11  13  13  NA  6  5  5  2  MC  1  35  11  26  10  2  13  9  9  9  3  7  4  2  9  NA  6  5  5  2  Size  1  19  7  10  12  2  33  14  25  14  3  7  6  7  4  NA  2  2  0  0  LNM  0  17  8  11  11  1  18  11  11  10  2  10  4  9  2  3  14  3  9  7  NA  2  3  2  0 In addition, STAT3 with different TF partner pools among different subtypes may offer another mechanism for predicting prognostic features of STAT3 in different subtypes (Fig. 3C ).
LDHA and LDHB appear to be down-regulated by STAT3 and MYC in both 90 A and 72 A cohorts and low LDHB mRNA levels in 90 A cohort are a predictor of favorable prognosis (Table 2) . High levels of IDH3G are a favorable prognosis predictor in 72 A cohort (Table 3) . ESRRG, PC, a transcript variant of MYC, SDHD, and LDHB are highly expressed in the non-tumor component (Fig. 4B) . ii. Phenotype-like mesenchymal stem cells in tumor pathogenesis are predicted to be regulated by the STAT3 network. Western blot analysis for METAP2 encoded protein indicates it to be regulated by erα. We found increased p67 protein in MCF-7 with e 2 treatment as compared to that with fulvestrant (ICI 182, 780 or ICI) treatment, (ICI + e 2 ) treatment and control. MCF-7 cells were deprived of estrogen for 2 days and treated with 10
M e 2 (labeled as + e 2 ), 10 −7 M ICI183,780 (labeled as + ICI183,780), or a combination of both (ICI + e 2 ) for 48 hours. Total lysate (60 µg/lane) from MCF-7 cells was resolved in 7.5% SDS-PAge and immunoblotted with anti-rat p67. β-actin was as the loading control. The lower blot was probed with anti-β-actin. The upper right panel shows that a diagram of the network prediction for interaction between erα and STAT3 results in a switch in expression mode of their potential target gene-METAP2, which is predicted to be subtype relevant in er(+) IDCs (B). Moreover, METAP2 is predicted to be shared target genes due to the combinatorial interaction of 2 given transcription factors (see the overlapping network of MYCnSTAT3 and ESR1nSTAT3 in Table S2 .4 of Suppl. 2) but it is neither in the overlapping network of ESR1 and STAT3 nor in that of MYC and STAT3 (Table S2 .6 in Suppl. 2). Based on the network analysis results, the proposed interplay between promoter use pathways of ESR1 nSTAT3 and MYCnSTAT3 in luminal A and B in regulating METAP2 is proposed (B). The lower left panel demonstrates that DNA sequence of promoter region for rat MeTAP2 (p67) (genBank: U37710) includes 5 3′ ere half-sites 45 and a 5′Am2Tp2 variant site 46 (c). This indicates rat METAP2 to be a target gene of erα due to the half-ere sites to be the candidate binding sites of erα. The lower right panel demonstrates that DNA sequence of promoter region for mouse MeTAP2 (p67) includes two 5′ ere half-sites and two 3′ ere half-sites (D). This indicates mouse METAP2 to be a target gene of erα due to the half-ere sites to be the candidate binding sites of erα.
STAT3 network (Figs. 3D and 4C iii. An increased tumor survival mechanism via sustained angiogenesis involving STAT3.
We find functionally sustained angiogenesis to be FOXC1 is an additional partner of STAT3 (Fig. 3B , Tables S1.10 and S1.11). Importantly, we found that the mechanism for sustained angiogenesis driven by the STAT3 network in ER(−) BCs (Fig. 7B  9 ) is partially relevant in ER(+) BCs (Fig. 3B ). This may suggest that different transcriptional regulators interact with STAT3 to control tumor angiogenesis dependent upon different BC subtypes.
Other in vitro studies 29, 30 support the concept that (Fig. 4D) .
We further compared the functional subnetwork of FOXC1, which is an indicator of high mitotic count in triple negatives (Fig. 6D (Table 2 ). This regulatory event may be involved in the crosstalk between ERα and STAT3 that enhances a TAM resistance mechanism. This mechanism may be due to aberrant STAT3 activities on up-regulating key components in the PI3K, MAPK and c-SRC signaling pathways in ER(+) BCs. Interestingly, the gene expression for a few target genes (e.g. ABL1, GRB2, Figure 7 . heatmaps for the subnetworks of MYC and STAT3 and the proposed TAM resistance mechanism. We described the levels of gene expression for both erα and STAT3 by coloring with green for low and blue for high. The thickness of line indicates the degree of activities that are predicted to depend on the expression level of erα when STAT3 is elevated in triple negatives and er(+) infiltrating ductal breast carcinomas. erα is weakly expressed in triple negatives. Thus, it is possible that crosstalk between erα and STAT3 in TN is relatively weak. To this subset of patients, TAM treatment is not applied as one of the cancer therapies. On the other hand, the high possibility of TAM resistance in a subset of luminal A is proposed. The proposed mechanism of TAM resistance due to crosstalk between erα and STAT3 has been described in the main text. Figures 7A and B show the gene profilings of ERBB2 signaling molecules predicted to be regulated by STAT3 in coupling with MYC in triple negatives/erBB2+, groups Ie/IIe, respectively. Two corresponding non-tumor (NT) components are as the control gene profilings in this case (A and B) . Both MYC and STAT3 differentially up-regulate the mrNA expression for a subset of erBB2 signaling molecules among and/or within subtypes (A and B). The estrogen action on crosstalk between erα and STAT3 is mainly seen in luminal A (see arrows with thick lines colored with orange or dark blue in Fig. 7D ) but is weak in TN (see arrows with thin lines colored with orange or dark blue in Fig. 7C ). We describe phosphorylation at serine/threonine residues (The p is high-lighted by orange color), tyrosine residues (The p is high-lighted by yellow color) and the mixed types (The p is not high-lighted).
(c and D) are summarized from current review articles 10, 18 with a few modifications derived from our findings. In Figures 7C and D , the example of the most relevant target genes of STAT3 and/or erα are from our findings in Tables S1.4, S2.1, S2.3, S2.4 and S2.6.
MAP2K4 and ERBB2) in the ERBB2 signal transduction pathway mediated by STAT3 are conserved between ER(+) and ER(−) BCs (Figs. 7A and B) . With different TF partners of STAT3 among different subtypes, it may condition different mechanisms for predicting prognostic features of STAT3 in different subtypes. For instance, we found the expression levels of GRB2, NCK2, STAT3, PRKCB1, MAP2K4, ABL1, IGF2R, LYN, and VEGFA in the STAT3 network to be predictors for poor clinical outcome in the 90 A cohort. Alternately, the expression levels of NANOG, OIP5, LDHB, NRG1 and POU5F1 in the STAT3 network are predicted to be good prognostic factors in the 90 A cohort (Fig. 3F and Table 2 ). Moreover, there are 6 poor and 5 good prognostic factors in the STAT3 network of 72 A cohort (Fig. 3F and Table 3 Another chemotherapeutic drug resistance marker upregulated by the STAT3 network is RAF1 (Fig. 7B and Table S1 . Table 2 shows the results from survival analyses of 4 functional STAT3 subnetworks (Figs. 3B-D) , the FOXC1 subnetwork (Fig. 3E ) and the genes in the ERBB2 signal transduction pathway (Fig. 7B ). These pathways are potentially regulated by the STAT3 network in ER(+) IDCs. We found 9 poor prognostic factors and 5 good prognostic factors of the STAT3 network in the 90 A cohort (Fig. 3F and Table 2 ). Results for the 72 A cohort are listed in Table 3 and Figure 3F . The prognostic feature for STAT3 in ER(+) breast cancer was demonstrated by the components of functional STAT3 subnetworks that are also predictor(s) for clinical outcomes (Fig. 3F and Suppl. 6 in Additional file 1). Some were already validated by the literature, including The evaluation was made by the scatter plot analysis using data from hybridization (log 2 ratios) and qPCr (−∆Cps). The Pearson's correlation coefficient was used to find the linear relationships between mRNA expression levels derived from both log 2 ratios and −∆Cps for the gene of interest. A good correlation is indicated between array gene expression (log 2 ratio) and their corresponding qPCr data (−∆Cp) for eSr1(5561), Pgr(11809) and erBB2(764), respectively. The Agilent feature numbers are listed within the parenthesis next to the corresponding gene symbols. The 60 mer for PGR on array is for hybridizing with transcripts of PGR. The primer used for qPCR analysis only amplifies transcript variant 1 of PGR.
Heatmaps (Fig. 6A) Heatmaps in Figure 4 of network activities following gene expression show small variations in cell proliferation (Fig. 4A) , and the Warburg effect (Fig. 4B ) among subtypes but are enriched in luminal A. The FOXC1 subnetwork (Fig. 4D) shows increased transcriptional dynamics between non-tumor and tumor components as opposed to among tumor subtypes. However, the heatmaps for the ES-like phenotype (Fig. 4C ) in the ER(+) breast cancer population scattered with little dynamic change in gene expression patterns among subtypes. Heatmaps in Figure 4E show that approximately one third of the 90 A population (designated as subcohorts 1 and 3) have a distinct pattern of dynamic changes in a prognostic signature. To elucidate activities of this STAT3 subnetwork in relation to prognostic features of STAT3, we divided ER(+)IDCs (90 A cohort) into three subgroups based on the differential expression patterns of genes within the prognostic signature predicted to be controlled by STAT3 (Fig. 4E) .
Here, we suggest this 15 gene signature to be different from other published signatures. First, each functional transcription factor (e.g. STAT3) has its own transcriptional mechanisms predicted by network analysis. The target gene activities of STAT3 may also be regulated by other regulators. For instance, both MYC and STAT3 share target genes within the MYC and STAT3 transcriptional regulatory network. Network analysis allows dissection of STAT3 mediated transcriptional activities, although we only analyzed half a genome due to the microarray limitations. The most relevant STAT3 transcriptional regulatory network is predicted in a breast cancer model system that has a relatively small N number for 8 molecular subtypes. Second, the network analysis is a qualitative method. We observed a variable expression pattern of STAT3 target genes. As a result, the heatmaps (Fig. 9) show the transcriptional dynamics for the prognostic signature ruled by STAT3 only between subcohorts 1 and 3. Kaplan-Meier survival analysis predicts a poor prognostic feature in subcohort 1 (P = 0.001) as compared to subcohort 3. Table S6 .1 shows only univariate COXPH analysis of subcohort 1/non 1 to be significant but not those of subcohort 1/3, subcohort 2/3, subcohort 1/2, subcohort 2/non 2, subcohort 3/non 3 and nine major traditional prognostic factors. Additionally, no multivariate COXPH analysis of tested prognostic factors shows significance. Upper panel shows the heatmaps of a prognosis relevant gene set in 3 sample groups-NT, subcohorts 1 and 3 (A). Subcohort 1 has the STAT3 subnetwork (total 17 probes) that is predicted to be activated due to high levels of STAT3. Subcohort 3 has the STAT3 subnetwork (total 17 probes) that is predicted to be suppressed due to low levels of STAT3. NT stands for non-tumor components. Light red color bar stands for subcohort 1 (see Fig. 7e ). Light green color bar stands for subcohort 3 (see Fig. 7e ). The functional annotation of 17 probes (Y axis) and clinical array IDs (X axis) are displayed along with the heatmaps generated by unsupervised clustering (A). Lower panel shows the significant difference in the clinical outcome of subcohort 1 as compared to that of subcohort 3. Kaplan-Meier curves estimate the association between 2 subcohorts and their overall survival probabilities (see method). To correlate clinical outcomes, we calculated the probability of "cancer specific overall survival" in 2 subcohorts (1 and 3) in the ER(+) infiltrating ductal carcinomas. Overall survival was defined as the time interval between the first date of breast tumor surgery and the last follow-up date or date of death. The numerical number within the parentheses next to each subcohort means the total patient number in each subcohort.
conclusions
The prognostic value of STAT3 in an ER(+) breast cancer cohort model (90 A cohort) is unfavorable. This is indicated by a prognosis relevant gene signature within the STAT3 network, which is also relevant to the development of malignant phenotypes and biochemical responses in an ER(+) breast cancer population enriched in luminal A subtype.
In this study, we have successfully dissected the functional transcriptome, which includes statistically identified STAT3 target genes, to establish poor prognostic features of STAT3 in a subtype enriched breast cancer population. We conclude the most relevant mechanisms contributing to the prognosis and/or subtype relevant features of STAT3 in ER(+) breast cancers are associated with multiple activities mainly crosstalk between and among (STAT3, ERα), (STAT3, MYC), (STAT3, MYC, ERα) and the action of STAT3.
2 novel findings from network analysis establish the mechanisms that support an interpretation for a STAT3 role in treatment response and in ER(+) breast cancer development. First, tamoxifen resistance is enhanced by crosstalk between ERα and STAT3. ERα plays a major role in activating STAT3 via the non-genomic pathway. Activated STAT3 is predicted to preferentially up-regulate genes coding for enzymes and adaptors shared by many key oncogenic signal transduction pathways including MAPK/ERK signaling. As a result, this may enhance ER(+) tumor resistance to 4-hydroxyl tamoxifen treatment predominantly in the luminal A subtype. Second, the competitive regulatory mode between ERα and STAT3 that differentially regulates shared target genes is subtype enriched. For instance, METAP2 is up-regulated in luminal B and down-regulated in luminal A via the subtype relevant promoter pathways (Fig. 5C) . Importantly, we have validated this transcriptional regulatory mechanism via the combinatorial interaction between ERα and STAT3 in regulating METAP2 (p67) protein expression in a luminal B breast cancer cell model.
Another major control mechanism is triggered by crosstalk between STAT3 and MYC. We demonstrate that the overlapping network of MYC and STAT3, identified in ER(+) breast cancers, involves 4 malignant phenotypes: proliferation, sustained angiogenesis, ES-like phenotype and the Warburg effect. In addition, we identify network genes that overlap with genes contributing to the development of 10 clinical parameters and 12 cancer related signal transduction pathways. However, these gene expression patterns are less aggressive than those in ER(−) BCs. This may, in part, be due to different pre-programmed TF partners of STAT3 that differentially determine tumor cell fate between ER(+) and ER(−) subtypes.
Additionally, 3 important findings identify STAT3 as a central regulator in ER(+) BCs, including its action contributing to the prognosis and/or subtype relevant features of STAT3 in ER(+) breast cancers. They are (1) the major clinically relevant STAT3 partner is MYC and more than 100 TF partners are the components of STAT3 network; (2) high expression of NANOG or RAF1 in the STAT3 network may cause chemodrug resistance and elevated levels of CCND1 by STAT3 regulation may cause TAM resistance, which have been supported by numerous in vitro studies; [34] [35] [36] (3) the prognostic relevant gene set, which is also the target gene set of STAT3, is poor clinical outcome predictor in 2 ER(+) breast cancer subcohorts. It contains relatively high levels of GRB2, LYN, IGF2R, VEGFA, STAT3, NCK2, OIP5 and ABL1 and low levels of MAP2K4, PRKCB, POU5F1 and NRG1, indicating poor prognosis. Low levels of LDHB and NANOG predict good prognosis. Several potential therapeutic targets have been identified (e.g. VEGFA, STAT3, ABL1, IGF2R and LYN) within this prognostic relevant gene set.
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